DrugDashboards

Lodoco

Colchicine Tablets 0.5 mg · COLCHICINE .5 mg/1 · Tablet · Oral · AGEPHA Pharma USA, LLC

NDC 82867-0001-01 · 1 BLISTER PACK in 1 CARTON / 30 TABLET in 1 BLISTER PACK · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $17.00 per unit over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$17.00per EAinvoice-surveyed acquisition cost · Dec 29, 2025
  • Part D plans paid (avg)$15.74per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$17.77per unitnegotiated price across 19 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$12.35per unitAgepha Pharma USA, LLC · Jan 1, 202573% of what pharmacies pay — a deeper discount than 71% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$17.77per unit
middle half $17.12$17.90 · 19 plans · Apr 1, 2026
Est. net of rebates
$10.66–$13.32
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
0%of plans cover it
tier 4 · prior auth 100% · step therapy 0% · qty limit 68%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$10.00$20.00Feb 2025Dec 2025$17.00
7 price points · per EA · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$509.98
#90 count
$1529.95

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$82,727
165 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.0%chance of a new FDA shortage posting for colchicine tablets 0.5 mg (oral solid) in the next 90 days

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA215727
TE code
Approval date
Jun 16, 2023
Patents / exclusivity
13 patents, 0 exclusivities
TypeNumber / codeExpires
patent10130585May 9, 2034
patent12233035Nov 1, 2033
patent11026901Nov 1, 2033
patent11026900Nov 1, 2033
patent11026899Nov 1, 2033
patent10842762Nov 1, 2033
patent10265281Nov 1, 2033
patent10206891Nov 1, 2033
patent9744144Nov 1, 2033
patent11944594Nov 1, 2033
patent12280025Nov 1, 2033
patent12364675Nov 1, 2033

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Colchicine Tablets 0.5 mg (Tablet)

LabelerStrengthFirst seenLast seen
AGEPHA Pharma USA, LLCCOLCHICINE .5 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lodoco — NDC 82867-0001-01," retrieved September 3, 2026, https://drugdashboards.com/drug/82867000101.

Free to cite with attribution — see how the data is put together.